TY - JOUR
T1 - Multicenter comparison of 18F-FDG and 68Ga-DOTA-peptide PET/CT for pulmonary carcinoid
AU - Lococo, Filippo
AU - Perotti, Germano
AU - Cardillo, Giuseppe
AU - De Waure, Chiara
AU - Filice, Angelina
AU - Graziano, Paolo
AU - Rossi, Giulio
AU - Sgarbi, Giorgio
AU - Stefanelli, Antonella
AU - Giordano, Alessandro
AU - Granone, Pierluigi
AU - Rindi, Guido
AU - Versari, Annibale
AU - Rufini, Vittoria
PY - 2015/3/13
Y1 - 2015/3/13
N2 - PURPOSE: The aims of this study were to retrospectively evaluate and compare the detection rate (DR) of Ga-DOTA-peptide and F-FDG PET/CT in the preoperative workup of patients with pulmonary carcinoid (PC) and to assess the utility of various functional indices obtained with the 2 tracers in predicting the histological characterization of PC, that is, typical versus atypical. METHODS: Thirty-three consecutive patients with confirmed PC referred for F-FDG and Ga-DOTA-peptide PET/CT in 2 centers between January 2009 and April 2013 were included. The semiquantitative evaluation included the SUVmax, the SUV of the tumor relative to the maximal liver uptake for F-FDG (SUVT/L) or the maximal spleen uptake for Ga-DOTA-peptides (SUVT/S), the ratio between SUVmax of Ga-DOTA-peptides PET/CT, and the SUVmax of F-FDG PET/CT (SUVmax ratio). Histology was used as reference standard. RESULTS: Definitive diagnosis consisted of 23 typical carcinoids (TCs) and 10 atypical carcinoids. F-FDG PET/CT was positive in 18 cases and negative in 15 (55% DR). Ga-DOTA-peptide PET/CT was positive in 26 cases and negative in 7 (79% DR). In the subgroup analysis, Ga-DOTA-peptide PET/CT was superior in detecting TC (91% DR; P <0.001), whereas F-FDG PET/CT was superior in detecting atypical carcinoid (100% DR; P = 0.04). The SUVmax ratio was the most accurate semiquantitative index in identifying TC. CONCLUSIONS: Overall diagnostic performance of PET/CT in detecting PC is optimal when integrating F-FDG and Ga-DOTA-peptide PET/CT findings. In the subgroup analysis, the SUVmax ratio seems to be the most accurate index in predicting TC. Both methods should be performed when PC is suspected or when the histological subtype is undefined.
AB - PURPOSE: The aims of this study were to retrospectively evaluate and compare the detection rate (DR) of Ga-DOTA-peptide and F-FDG PET/CT in the preoperative workup of patients with pulmonary carcinoid (PC) and to assess the utility of various functional indices obtained with the 2 tracers in predicting the histological characterization of PC, that is, typical versus atypical. METHODS: Thirty-three consecutive patients with confirmed PC referred for F-FDG and Ga-DOTA-peptide PET/CT in 2 centers between January 2009 and April 2013 were included. The semiquantitative evaluation included the SUVmax, the SUV of the tumor relative to the maximal liver uptake for F-FDG (SUVT/L) or the maximal spleen uptake for Ga-DOTA-peptides (SUVT/S), the ratio between SUVmax of Ga-DOTA-peptides PET/CT, and the SUVmax of F-FDG PET/CT (SUVmax ratio). Histology was used as reference standard. RESULTS: Definitive diagnosis consisted of 23 typical carcinoids (TCs) and 10 atypical carcinoids. F-FDG PET/CT was positive in 18 cases and negative in 15 (55% DR). Ga-DOTA-peptide PET/CT was positive in 26 cases and negative in 7 (79% DR). In the subgroup analysis, Ga-DOTA-peptide PET/CT was superior in detecting TC (91% DR; P <0.001), whereas F-FDG PET/CT was superior in detecting atypical carcinoid (100% DR; P = 0.04). The SUVmax ratio was the most accurate semiquantitative index in identifying TC. CONCLUSIONS: Overall diagnostic performance of PET/CT in detecting PC is optimal when integrating F-FDG and Ga-DOTA-peptide PET/CT findings. In the subgroup analysis, the SUVmax ratio seems to be the most accurate index in predicting TC. Both methods should be performed when PC is suspected or when the histological subtype is undefined.
KW - F-FDG
KW - Ga-DOTA-peptides
KW - PET/CT
KW - pulmonary carcinoid
UR - http://www.scopus.com/inward/record.url?scp=84922670247&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84922670247&partnerID=8YFLogxK
U2 - 10.1097/RLU.0000000000000641
DO - 10.1097/RLU.0000000000000641
M3 - Article
C2 - 25608152
AN - SCOPUS:84922670247
SN - 0363-9762
VL - 40
SP - e183-e189
JO - Clinical Nuclear Medicine
JF - Clinical Nuclear Medicine
IS - 3
ER -